Understand the medicine before the offer.

An ingredient and its brand names

Mounjaro and Zepbound both contain tirzepatide as their active ingredient.

Tirzepatide acts on gut hormones, body signals involved in appetite and how the body handles sugar.

A peptide is formed when tiny building parts join in a short chain. Proteins are larger substances made from those same parts.

Calling something a peptide describes its make-up; the name alone cannot show that a product has approval.

The brands have different approved uses.

As of September 26, 2026, Mounjaro was approved for type 2 diabetes, a condition that affects blood sugar.

Mounjaro also had approval to reduce the chance of heart attack, stroke, or death from heart or blood-vessel problems. This approval applied to adults who had type 2 diabetes and a high risk of those problems.

Mounjaro did not have a weight-loss approval at that date.

At the same check, Zepbound had approval for long-term weight management for adults who had obesity or who were overweight with a weight-related health problem.

Its approval also included adults with obesity whose obstructive sleep apnea was moderate to severe.

Sleep apnea means breathing repeatedly stops or becomes too shallow during sleep.

The container leaves questions unanswered.

As of September 26, 2026, approved tirzepatide was given by injection, meaning a shot. It came in medicine pens and small bottles called vials, including a pen holding several doses.

A medicine pen is a device for giving a shot; it is not a writing pen.

A vial alone does not tell you whether the product is compounded.

Ask who made the medicine and what the label calls it.

A generic is an FDA-approved version of a brand-name medicine, different from a medicine made to order.

As of that date, there was no FDA-approved generic tirzepatide.